Pharmacology and antitussive efficacy of 4-(3-trifluoromethylpyridin-2-yl)- piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 2, 2007, Pages 665-674

  Bhattacharya, Anindya ^a   Scott, Brian P ^a   Nasser, Nadia ^a   Ao, Hong ^a   Maher, Michael P ^a   Dubin, Adrienne E ^a   Swanson, Devin M ^a   Shankley, Nigel P ^a   Wickenden, Alan D ^a   Chaplan, Sandra R ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; 4 (3 TRIFLUOROMETHYL PYRIDIN 2 YL) PIPERAZINE 1 CARBOXYLIC ACID (5 TRIFLUOROMETHYL PYRIDIN YL) AMIDE; ANTITUSSIVE AGENT; CAPSAICIN; CITRIC ACID; CODEINE; JNJ 17203212; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; DRUG STRUCTURE; GUINEA PIG; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RADIOASSAY; TRACHEA;

AMINOPYRIDINES; ANIMALS; ANTITUSSIVE AGENTS; CHO CELLS; COUGH; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUINEA PIGS; MALE; PIPERAZINES; TRPV CATION CHANNELS;

EID: 35548999215     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.127258     Document Type: Article

References (41)

1. Ahern GP, Wang X, and Miyares RL (2006) Polyamines are potent ligands for the capsaicin receptor TRPV1. J Biol Chem 281:8991-8995.
2. Arunlakshana O and Schild H (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
3. Canning BJ, Mori N, and Mazzone SB (2006) Vagal afferent nerves regulating the cough reflex. Respir Physiol Neurobiol 152:223-242.
4. Carr MJ, Kollarik M, Meeker SN, and Undem BJ (2003) A role of TRPV1 in bradykinin-induced excitation of vagal airway afferent nerve terminals. J Pharmacol Exp Ther 304:1275-1279.
5. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, and Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389:816-824.
6. Cesare P, Moriondo A, Vellani V, and McNaughton PA (1999) Ion channels gated by heat. Proc Natl Acad Sci U S A 96:7658-7663.
7. Correll CC and Palani A (2006) Advances in the development of TRPV1 antagonists. Expert Opin Ther Pat 16:783-795.
8. De Petrocellis L and Di Marzo V (2005) Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. Life Sci 77:1651-1666.
9. Docherty RJ, Yeats JC, and Piper AS (1997) Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurones in culture. Br J Pharmacol 121:1461-1467.
10. Gatti R, Andre E, Amadesi S, Dinh TQ, Fischer A, Bunnett NW, Harrison S, Geppetti P, and Trevisani M (2006) Protease-activated receptor 2 activation exaggerates TRPV1-mediated cough in guinea pigs. J Appl Physiol 101:506-511.
11. Gavva NR, Bannon AW, Immke DC, Tamir R, Klinosky L, Hever G, Wang J, Kuang R, Wang W, Davis J, et al. (2006) Preclinical pharmacology of AMG517: a novel TRPV1 antagonist in the clinic. In Proceedings of the Annual Meeting of the Society for Neuroscience; 2006 Oct 14-18; Atlanta, GA. Program 51.21, Society for Neuroscience, Washington, DC.
12. Gavva NR, Kionsky L, Qu Y, Shi L, Tamir R, Edenson S, Zhang TJ, Viswanadhan VN, Toth A, Pearce LV, et al. (2004) Molecular determinants of vanilloid sensitivity in TRPV1. J Biol Chem 279:20283-20295.
13. Gavva NR, Tamir R, Qu Y, Klionsky L, Zhang TJ, Immke D, Wang J, Zhu D, Vanderah TW, Porreca F, et al. (2005) AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide] , a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 313:474-484.
14. Geppetti P, Materazzi S, and Nicoletti P (2006) The transient receptor potential vanilloid 1: role in airway inflammation and disease. Eur J Pharmacol 533:207-214.
15. Gill CH, Randall A, Bates SA, Hill K, Owen D, Larkman PM, Cairns W, Yusaf SP, Murdock PR, Strijbos PJ, et al. (2004) Characterization of the human HCN1 channel and its inhibition by capsazepine. Br J Pharmacol 143:411-421.
16. Groneberg DA, Niimi A, Dinh QT, Cosio B, Hew M, Fischer A, and Chung KF (2004) Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough. Am J Respir Crit Care Med 170:1276-1280.
17. Gunthorpe MJ, Hannan SL, Smart D, Jerman JC, Arpino S, Smith GD, Brough S, Wright J, Egerton J, Lappin SC, et al. (2007) Characterization of SB-705498, a potent and selective TRPV1 antagonist which inhibits capsaicin-, acid-, and heat-mediated activation of the vanilloid receptor. J Pharmacol Exp Ther 321:1183-1192.
18. Hellwig N, Plant TD, Janson W, Schafer M, Schultz G, and Schaefer M (2004) TRPV1 acts as a proton channel to induce acidification in nociceptive neurons. J Biol Chem 279:34553-34561.
19. Jia Y, McLeod RL, and Hey JA (2005) TRPV1 receptor: a target for the treatment of pain, cough, airway disease and urinary incontinence. Drug News Perspect 18:165-171.
20. Jia Y, McLeod RL, Wang X, Parra LE, Egan RW, and Hey JA (2002) Anandamide induces cough in conscious guinea pigs through VR1 receptors. Br J Pharmacol 137:831-836.
21. Kollarik M, Ru F, and Undem BJ (2007) Acid-sensitive vagal sensory pathways and cough. Pulm Pharmacol Ther 20:402-411.
22. Kollarik M and Undem BJ (2006) Sensory transduction in cough-associated nerves. Respir Physiol Neurobiol 152:243-254.
23. Kyle DJ and Tafesse L (2006) TRPV1 antagonists: a survey of the patent literature. Expert Opin Ther Pat 16:977-996.
24. Lalloo UG, Fox AJ, Belvisi MG, and Barnes PJ (1995) Capsazepine inhibits cough induced by capsaicin and citric acid but not by hypertonic saline in guinea pigs. J Appl Physiol 79:1082-1092.
25. Lewis CA, Ambrose C, Banner K, Battram C, Butler K, Giddings J, Mok J, Nasra J, Winny C, and Poll C (2007) Animal models of cough: L=literature review and presentation of a novel cigarette smoke-enhanced cough model in the guinea pig. Pulm Pharmacol Ther 20:325-333.
26. Liu L and Simon SA (1997) Capsazepine, a vanilloid receptor antagonist, inhibits nicotinic acetylcholine receptors in rat trigeminal ganglia. Neurosci Lett 228:29-32.
27. Mazzone SB (2004) Sensory regulation of the cough reflex. Pulm Pharmacol Ther 17:361-368.
28. McIntyre P, McLatchie LM, Chambers A, Phillips E, Clarke M, Savidge J, Toms C, Peacock M, Shah K, Winter J, et al. (2001) Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Br J Pharmacol 132:1084-1094.
29. McLeod RL, Fernandez X, Correll CC, Phelps PT, Jia Y, Wang X, and Hey JA (2006) TRPV1 antagonists attenuate antigen-provoked cough in ovalbumin sensitized guinea pigs. Cough 2:10.
30. Rami HK, Thompson M, Stemp G, Fell S, Jerman JC, Stevens AJ, Smart D, Sargent B, Sanderson D, Randall AD, et al. (2006) Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 16:3287-3291.
31. Ricciardolo FLM (2001) Mechanism of citric acid-induced bronchoconstriction. Am J Med 111:18S-24S.
32. Ross RA (2003) Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 140:790-801.
33. Savidge J, Davis C, Shah K, Colley S, Phillips E, Ranasinghe S, Winter J, Kotsonis P, Rang H, and McIntyre P (2002) Cloning and functional characterization of the guinea pig vanilloid receptor 1. Neuropharmacology 43:450-456.
34. Shimizu I, Iida T, Horiuchi N, and Caterina MJ (2005) 5-Iodoresiniferatoxin evokes hypothermia in mice and is a partial transient receptor potential vanilloid 1 agonist in vitro. J Pharmacol Exp Ther 314:1378-1385.
35. Swanson DM, Dubin AE, Shah C, Nasser N, Chang L, Dax SL, Jetter M, Breitenbucher JG, Liu C, Mazur C, et al. (2005) Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J Med Chem 48:1857-1872.
36. Szallasi A, Cortright DN, Blum CA, and Eid SR (2007) The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 6:357-372.
37. Tominaga M and Tominaga T (2005) Structure and function of TRPV1. Pflugers Arch 451:143-150.
38. Trevisani M, Milan A, Gatti R, Zanasi A, Harrison S, Fontana G, Morice AH, and Geppetti P (2004) Antitussive activity of iodo-resiniferatoxin in guinea pigs. Thorax 59:769-772.
39. Valenzano KJ, Grant ER, Wu G, Hachicha M, Schmid L, Tafesse L, Sun Q, Rotshteyn Y, Francis J, Limberis J, et al. (2003) N-(4- Tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H) -carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. In vitro characterization and pharmacokinetic properties. J Pharmacol Exp Ther 306:377-386.
40. Walker KM, Urban L, Medhurst SJ, Patel S, Panesar M, Fox AJ, and McIntyre P (2003) The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 304:56-62.
41. Watanabe N, Horie S, Michael GJ, Keir S, Spina D, Page CP, and Priestley JV (2006) Immunohistochemical co-localization of transient receptor potential vanilloid (TRPV) 1 and sensory neuropeptides in the guinea pig respiratory system. Neuroscience 141:1533-1543.